Understanding the FDA Boxed Warning

Every GLP-1 receptor agonist approved in the United States carries a boxed warning (sometimes called a "black box warning") regarding the risk of thyroid C-cell tumors, including medullary thyroid carcinoma. This is the most serious type of FDA warning and deserves careful examination of its origins and clinical relevance.

The warning states: "In rodents, [semaglutide] causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether [semaglutide] causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans, as the human relevance of [semaglutide]-induced rodent thyroid C-cell tumors has not been determined."

This language is important because it explicitly acknowledges that the rodent findings may not apply to humans. The warning exists as a precautionary measure while long-term human data continue to accumulate. At Form Blends, we discuss this warning with every patient during our consultation process to ensure fully informed decision-making. consultation process

The Rodent Evidence: What Was Found

The thyroid cancer concern originated from mandatory preclinical toxicology studies conducted in rats and mice before GLP-1 receptor agonists could be tested in humans.

Rat Studies

In two-year carcinogenicity studies, rats treated with liraglutide, semaglutide, and other GLP-1 receptor agonists developed thyroid C-cell hyperplasia, C-cell adenomas, and C-cell carcinomas (MTC) at rates significantly higher than control animals. The effect was dose-dependent and duration-dependent, meaning higher doses and longer treatment produced more tumors.

With semaglutide specifically, thyroid C-cell tumors were observed at all doses tested, including doses as low as 0.01 mg/kg/day (which produces systemic exposures comparable to the maximum recommended human dose). The tumors included both benign adenomas and malignant carcinomas.

Mouse Studies

Mouse carcinogenicity studies with semaglutide showed C-cell hyperplasia but lower rates of frank C-cell tumors compared to rats. This species difference is relevant to the question of human applicability.

Why Rats Develop These Tumors

Rat thyroid C-cells express abundant GLP-1 receptors. When chronically stimulated by GLP-1 receptor agonists, these cells proliferate and can undergo malignant transformation. Calcitonin, the hormone produced by C-cells, increases in rats treated with GLP-1 receptor agonists, reflecting C-cell activation and hyperplasia.

The key mechanistic question is whether human thyroid C-cells respond similarly to chronic GLP-1 receptor stimulation.

Species Differences: Why Rats Are Not Humans

Several important biological differences between rat and human thyroid C-cells suggest the rodent findings may not translate to humans.

GLP-1 Receptor Expression

Multiple studies have examined GLP-1 receptor expression in human thyroid tissue. The findings have been variable:

• A 2010 study using immunohistochemistry detected GLP-1 receptors on human C-cells, but subsequent studies questioned the antibody specificity
• More rigorous studies using validated antibodies and RNA-based methods (in situ hybridization, RT-PCR) have found little to no GLP-1 receptor mRNA in normal human thyroid C-cells
• A 2015 study using a validated GLP-1 receptor antibody found receptor expression in human MTC tumors but minimal expression in normal C-cells
• Single-cell RNA sequencing data from human thyroid tissue shows very low GLP-1 receptor transcript levels in C-cells compared to other cell types

The preponderance of evidence suggests that human thyroid C-cells have much lower GLP-1 receptor expression than rat C-cells, which would explain why chronic GLP-1 receptor stimulation produces C-cell tumors in rats but may not do so in humans.

Calcitonin Response

In rats, GLP-1 receptor agonists consistently increase serum calcitonin levels, reflecting C-cell stimulation. In human clinical trials, semaglutide and other GLP-1 receptor agonists do not increase serum calcitonin levels. This is a critical observation because calcitonin is a sensitive biomarker of C-cell activity.

Multiple studies across the SUSTAIN, PIONEER, and STEP programs have monitored calcitonin levels and found no meaningful differences between semaglutide and placebo groups. Individual calcitonin elevations were rare and not dose-dependent.

C-Cell Density

Rat thyroid glands contain substantially more C-cells relative to total thyroid tissue compared to human thyroid glands. Rats have approximately 1 to 2% C-cell content, while humans have only about 0.1%. This difference in baseline C-cell mass may contribute to the species-specific susceptibility to C-cell tumor formation.

Human Clinical Trial Data

The most relevant evidence for assessing thyroid cancer risk in humans comes from the clinical trials themselves. Across the GLP-1 receptor agonist trial program, tens of thousands of patients have been followed for years.

Semaglutide-Specific Trial Data

The total number of MTC cases across all semaglutide trials remains extremely small and is not statistically different from placebo groups. In the SELECT trial, which had the largest enrollment and longest follow-up, 5 cases occurred in the semaglutide group versus 3 in the placebo group, a difference that could easily be attributed to chance given the background incidence of MTC.

Class-Wide Trial Data

When all GLP-1 receptor agonist CVOTs are pooled (LEADER, SUSTAIN-6, HARMONY, REWIND, PIONEER-6, EXSCEL, ELIXA, SELECT), the total MTC event rate remains consistent with the expected background incidence in the general population. A 2023 meta-analysis of GLP-1 RA trials found no statistically significant increase in thyroid cancer of any type.

Epidemiological Studies

Population-based observational studies provide an additional lens for evaluating thyroid cancer risk with GLP-1 receptor agonists. These studies examine real-world populations and can detect signals that might be missed in clinical trials with selected populations.

French National Healthcare Database Study

A 2022 study using the French national healthcare database analyzed over 2.5 million patients with type 2 diabetes. After up to 10 years of follow-up, GLP-1 receptor agonist use was associated with a modestly increased signal for thyroid cancer overall (HR approximately 1.3 to 1.6), but the absolute risk remained extremely small. Importantly, this study could not distinguish between MTC (the type linked to rodent data) and papillary thyroid carcinoma (the most common type, which is not linked to GLP-1 receptor activation).

Limitations of this study included inability to confirm histological subtypes, potential detection bias (patients on GLP-1 RAs receive more medical attention, leading to more thyroid nodule detection), and unmeasured confounders.

Scandinavian Registry Studies

Studies using Nordic healthcare registries have generally not found increased thyroid cancer risk with GLP-1 receptor agonist use. A Danish study with 12 years of follow-up found no association between incretin-based therapy (GLP-1 RAs and DPP-4 inhibitors) and thyroid cancer.

FDA Adverse Event Reporting System (FAERS)

FAERS analyses have shown a disproportionate number of thyroid cancer reports for GLP-1 receptor agonists compared to other diabetes medications. However, FAERS data suffer from significant reporting biases. Because patients and clinicians are aware of the boxed warning, they are more likely to report thyroid-related events for GLP-1 RAs than for other medications. This creates a detection bias that inflates the apparent signal.

Medullary Thyroid Carcinoma: Background Context

To properly contextualize the risk, understanding MTC is essential. MTC originates from thyroid C-cells and accounts for approximately 1 to 2% of all thyroid cancers. The annual incidence in the United States is approximately 0.2 per 100,000 persons, making it a very rare cancer.

Approximately 25% of MTC cases are hereditary, associated with RET proto-oncogene mutations (MEN2 syndrome). The remaining 75% are sporadic. Risk factors for sporadic MTC are poorly understood, but they do not include obesity or diabetes, the primary populations taking GLP-1 receptor agonists.

The clinical significance of the boxed warning must be weighed against MTC's extreme rarity. Even if GLP-1 receptor agonists produced a small increase in MTC risk (which current evidence does not confirm), the absolute risk would be measured in single-digit cases per million patient-years of treatment.

Current Screening and Monitoring Recommendations

Given the precautionary nature of the boxed warning, clinical guidelines and the prescribing information provide the following recommendations:

Contraindications

• Personal history of MTC
• Family history of MTC
• Multiple Endocrine Neoplasia syndrome type 2 (MEN2)

Monitoring During Treatment

• Routine serum calcitonin monitoring is not recommended by the prescribing information or most endocrine societies. The positive predictive value of calcitonin screening in the general population is too low to be clinically useful
• If calcitonin is measured and found to be elevated, thyroid evaluation with ultrasound should be performed
• Patients should be counseled to report symptoms such as a neck mass, dysphagia (difficulty swallowing), dyspnea (difficulty breathing), or persistent hoarseness

At Form Blends, we follow these guidelines in our clinical practice. We screen all patients for personal and family history of MTC and MEN2 before prescribing GLP-1 medications. prescribing safety

Risk-Benefit Analysis

The practical clinical question is whether the theoretical thyroid cancer risk outweighs the proven benefits of GLP-1 receptor agonists. The evidence strongly favors treatment in appropriate patients.

Quantifying the Potential Risk

The background incidence of MTC is approximately 2 per 1,000,000 persons per year. Even if GLP-1 receptor agonists doubled this risk (which current evidence does not support), the absolute increase would be approximately 2 additional cases per 1,000,000 patient-years.

Quantifying the Proven Benefits

• Cardiovascular: 14% reduction in MACE, 12% reduction in all-cause mortality
• Weight loss: 10 to 20% body weight reduction
• Kidney: 24% reduction in major kidney events
• Liver: Up to 59% NASH resolution
• Metabolic: Significant improvements in blood sugar, blood pressure, and lipids

When the proven, substantial benefits are weighed against an unconfirmed, extremely small theoretical risk, the benefit-risk ratio strongly favors GLP-1 receptor agonist use in appropriate patients without MTC risk factors.

Ongoing Research and Surveillance

The scientific community continues to monitor thyroid cancer risk through several mechanisms:

• Post-marketing surveillance: Ongoing FAERS monitoring and periodic safety reviews by the FDA
• Long-term extension studies: Some CVOT participants continue to be followed for thyroid outcomes
• Cancer registries: SEER (Surveillance, Epidemiology, and End Results) and similar registries track MTC incidence trends that could reveal population-level signals
• Mechanistic studies: Research continues on human thyroid C-cell GLP-1 receptor biology
• Calcitonin monitoring substudies: Some ongoing trials include serial calcitonin measurements to detect any early C-cell stimulation

The commitment to ongoing surveillance reflects appropriate scientific caution while the weight of evidence continues to be reassuring.

Frequently Asked Questions

Should I be worried about thyroid cancer if I take semaglutide?

Based on current evidence, the thyroid cancer risk for humans taking semaglutide appears to be extremely low. The boxed warning is based on rodent data that may not apply to humans because of significant biological differences between rat and human thyroid cells. Over 60,000 patients have been studied in clinical trials without a confirmed increase in thyroid cancer risk. However, if you have a personal or family history of MTC or MEN2 syndrome, you should not take semaglutide.

Do I need regular thyroid screening while on semaglutide?

Routine thyroid ultrasounds or calcitonin blood tests are not recommended for all patients on semaglutide. These tests can produce false positives that lead to unnecessary procedures. You should report any new neck symptoms (a lump, difficulty swallowing, or persistent hoarseness) to your doctor promptly. Standard thyroid function tests (TSH) are not related to C-cell tumors and are not useful for monitoring this specific risk.

What is the difference between medullary thyroid cancer and regular thyroid cancer?

Medullary thyroid carcinoma (MTC) arises from C-cells, which produce calcitonin. It accounts for only 1 to 2% of thyroid cancers. Papillary thyroid carcinoma, the most common type (80% of cases), arises from different cells (follicular cells) and is not linked to GLP-1 receptor signaling. The boxed warning pertains specifically to MTC, not thyroid cancer in general.

Has anyone actually developed thyroid cancer from semaglutide?

Small numbers of thyroid cancer cases have been reported in both semaglutide and placebo groups across clinical trials. The rates are not statistically different between groups. It is not possible to determine whether any individual case was caused by the medication or occurred coincidentally. Given the background rate of thyroid cancer in the general population, some cases are expected regardless of treatment.

Why does the FDA require a boxed warning if the risk is uncertain?

FDA boxed warnings are issued when there is a potential for serious harm, even if the evidence is not conclusive. The rodent carcinogenicity data met the threshold for a precautionary warning. The FDA acknowledges the uncertainty by including language stating that the human relevance is unknown. This approach errs on the side of patient safety and informed consent.

Should I get genetic testing for MEN2 before starting semaglutide?

Genetic testing for RET mutations (associated with MEN2) is not routinely recommended before starting GLP-1 receptor agonists. Screening through personal and family history is sufficient for most patients. If you have a family history of MTC, pheochromocytoma, or hyperparathyroidism, genetic counseling and testing may be appropriate before starting therapy. Our physicians at Form Blends conduct thorough history screening as part of the evaluation process. medical evaluation

Are some GLP-1 medications safer for the thyroid than others?

All GLP-1 receptor agonists carry the same boxed warning because all produce thyroid C-cell tumors in rodents. There are no convincing data showing that one GLP-1 receptor agonist has a different thyroid safety profile than another in humans. The choice of medication should be based on efficacy, tolerance, convenience, and cost rather than perceived differences in thyroid risk.

Conclusion

The thyroid cancer concern with semaglutide requires thoughtful evaluation of the evidence rather than reflexive alarm. The rodent data are real, but substantial biological evidence suggests they do not translate to humans. Clinical trials involving tens of thousands of patients have not confirmed an increased thyroid cancer risk. The boxed warning serves an important precautionary function while the proven benefits of GLP-1 therapy for cardiovascular, metabolic, kidney, and liver health are well-established.

At Form Blends, we take the thyroid safety question seriously and discuss it openly with our patients. Our physician-supervised approach ensures that appropriate screening is performed and that patients can make fully informed treatment decisions. get started Starting at $199/mo